产品中心
  Wechat

Wechat

  Contact Us

Address:

5th floor, Building 9, No.8 Shengmingyuan Road, Life Science Park, Zhongguancun, Changping District, Beijing, China

Email:

postmaster@sinotau.com

Tel:

+86-10-8492479489934358

Fax:

+86-10-84920734

Who We Are


Sinotau Pharmaceutical Group was founded in 2004 with one clear mission in mind, to provide "healthier lives" to patients in China. Through years of R&D efforts our company has developed three clear scopes within the Group, a more traditional generic Pharma arm, an innovative biological initiative and a nuclear medicine (Radiopharmaceutical) enterprise.  


Hainan Sinotau is the Group's subsidiary engaged in R&D, marketing and distribution in China of both domestic and imported generic portfolio. The company has more than 30 listed products in the market following an ambitious expansion of our current pipeline. Our generic business distributes our products to all provinces and regions in China. In 2014, Sinotau acquired two manufacturing sites in Sichuan and Guangdong provinces to further strengthen the capability and competitiveness of the Group. At present, Sinotau has several relevant generic applications under review at CFDA. After the approval of these products our portfolio will cover a broad array of key therapies across multiple indications and areas of critical need. 


SinotauBio is the Group's unit focused on the early development of novel antibodies and it is determined to become the World's leading developer of new monoclonal antibodies. SinotauBio has currently two research labs, one in Zongguancun Life Science Park in Beijing and the other in Birmingham city in Alabama (USA). These two sites concentrate their energies in R&D for oncology, neurodegenerative and autoimmune diseases, among other fields. One of this monoclonal antibody, CTB006, has received approval for Phase I-III Clinical Trials. Studies will be conducted in 1st tier hospitals, including the General Hospital of People's Liberation Army in Beijing. 


Sinotau Radiopharmaceutical is focused on development of a neurologic precision diagnostics pipeline with a focus on neurodegenerative diseases, oncology and other relevant afflictions. In 2016, Sinotau Group and Enigma Biomedical Group, a Canadian company, formed Cerveau Technologies, Inc., in Boston (USA) to help the global development of Sinotau's Radiopharmaceutical pipeline. In December of that same year Cerveau signed an exclusive license agreement with Merck Sharp & Dohme for the global development and commercialization of the investigational imaging agent MK-6240. Also in 2016 Sinotau signed an exclusive agreement with US company FluoroPharma Medical Imaging, Inc. to develop and commercialize patented cardiac imaging products CardioPET and BFPET in China and Canada. To support this growing nuclear medicine pipeline Sinotau is in close cooperation with world's leading experts to build up a network of sites that will cover most of the Radiopharmaceutical users in the country.


Sinotau is transforming into a modern leading player in the Chinese market with integrated domestic and international resources for R&D, marketing, manufacturing and distribution. The company aims to accurately diagnose and treat, and focuses on innovative pharmaceuticals and biologicals. The ultimate goal is to become an integrated solutions provider of early prevention, diagnosis and treatment for patients across China and rest of the World through precise products, R&D and quality manufacturing processes.